PHR:NYE-Phreesia Inc (USD)

COMMON STOCK | Health Information Services | NYE

Last Closing Price

USD 25.45

Change

0.00 (0.00)%

Market Cap

USD 1.33B

Volume

0.58M

Avg Analyst Target

USD 34.60 (+35.95%)

Avg User Target

USD
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict


PHR Stock Forecast & Price:
Based on the Phreesia Inc stock forecasts from 11 analysts, the average analyst target price for Phreesia Inc is USD 34.60 over the next 12 months. Phreesia Inc’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Phreesia Inc is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, Phreesia Inc’s stock price was USD 25.45. Phreesia Inc’s stock price has changed by -2.00% over the past week, +25.25% over the past month and -59.25% over the last year.

About Phreesia Inc (PHR:NYE)

Phreesia, Inc. provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. Its Phreesia Platform offers a suite of solutions to manage the patient intake process, as well as an integrated payments solution for proce ...Read More

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2022-07-04 )

Largest Industry Peers for Health Information Services

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VEEV Veeva Systems Inc Class A

N/A

USD31.61B 78.50 53.07
DOCS Doximity Inc

N/A

USD7.03B 52.46 59.23
TDOC Teladoc Inc

N/A

USD5.61B N/A -1.02
AGTI Agiliti Inc

N/A

USD2.87B 93.83 13.96
EVH Evolent Health Inc

N/A

USD2.85B N/A 52.64
AMWL American Well Corp

N/A

USD1.20B N/A -3.12
CNVY Convey Holding Parent Inc

N/A

USD0.76B N/A 28.29
BBLN Babylon Holdings Ltd

N/A

USD0.42B N/A -1.17
CSLT Castlight Health Inc

N/A

USD0.34B N/A N/A
NXU Novus Capital Corporation II

N/A

N/A N/A N/A

ETFs Containing PHR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Health Information Services)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -38.91% 33% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -38.91% 33% F 11% F
Trailing 12 Months  
Capital Gain -59.25% 38% F 8% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -59.25% 38% F 7% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 31.26% 63% D 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.26% 63% D 89% B+
Risk Return Profile  
Volatility (Standard Deviation) 65.60% 50% F 12% F
Risk Adjusted Return 47.66% 75% C 64% D
Market Capitalization 1.33B 44% F 56% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Health Information Services)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 2.91 100% A+ 95% A
Price/Book Ratio 3.47 56% F 22% F
Price / Cash Flow Ratio -17.80 89% B+ 90% A-
EV/EBITDA -7.93 100% A+ 89% B+
Management Effectiveness  
Return on Equity -35.82% 33% F 8% F
Return on Invested Capital -33.53% 22% F 6% F
Return on Assets -19.17% 22% F 3% F
Debt to Equity Ratio 0.03% 100% A+ 94% A
Technical Ratios  
Dividend Yield N/A N/A N/A N/A N/A
Short Ratio 2.84 67% D+ 41% F
Short Percent 7.20% 44% F 36% F
Beta 1.39 40% F 26% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

Discussions

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Underpriced compared to earnings

The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.